

**LABORATORY INVESTIGATION REPORT**

<b>Patient</b>	[REDACTED]	<b>UHID</b>	: AIGG.20965929	<b>Facility</b>	: AIG Hospitals, Gachibowli
<b>Episode</b>	: IP	<b>Ref. Doctor</b>	: Dr. RUPA BANERJEE	<b>Collec. Date</b>	: [REDACTED] 19:22
<b>Sample No</b>	: AGI1030488A	<b>Report Date</b>	: [REDACTED] 03:33		
<b>Ack. Date</b>	: [REDACTED] 00:43				

**Coagulation**

TEST	RESULT	UNIT	BIOLOGICAL REF INTERVAL
<b>PT WITH INR</b>			
Sample Type- Citrated Plasma			
<b>PROTHROMBIN TIME</b>	12.3	Seconds	10.8 - 13.3
Method - Photometric Clotting Assay			
<b>MEAN NORMAL PROTHROMBIN TIME</b>	12.1	Seconds	
Method - Photometric clotting assay			
<b>INR</b>	1.02	-	Normal <1.3 Therapeutic Range 2.0-3.5 Critical Alert >4.0

*Comments: Prothrombin time measures the extrinsic coagulation pathway which consists of activated Factor VII (VIIa), tissue factor and proteins of the common pathway (Factors X, V, II & Fibrinogen). Prolonged PT Administration of oral anticoagulant drugs Liver disease, particularly obstructive jaundice Vitamin K deficiency Disseminated intravascular coagulation Inherited deficiency of factors in extrinsic pathway (VII) and common pathway (V, X, prothrombin and fibrinogen) International Normalized Ratio 'endash' is used for defining the therapeutic ranges for anticoagulant therapy. Appropriate therapeutic range varies with the disease and treatment intensity. Recommended Therapeutic range for Oral Anticoagulant therapy INR 2.0-3.5: Treatment of Venous thrombosis & Pulmonary embolism, Prophylaxis of Venous thrombosis (High risk surgery), Prevention of systemic embolism in tissue heart valves, AMI, Valvular heart disease & Atrial fibrillation, Bileaflet mechanical valve in aortic position.*

*Note : 1. Results should be clinically correlated  
2. Test done on citrated plasma.*

Report Saved By - RAJESH KUMAR [REDACTED] 03:33 AM)

End of Report

*K. Vishnu Vardhan Kommu*

Dr. VISHNU VARDHAN KOMMU  
Pathologist